Start here if you're new
what it is
Gossamer Bio makes drugs for immune disease, inflammation, and cancer.
how it gets paid
Last year Gossamer Bio made $115M in revenue. Collaboration revenue was the main engine at $68M, or 59% of sales.
what just happened
Gossamer Bio posted $35M in quarterly revenue, and per-share loss was -$0.54.
At a glance
C+ balance sheet — struggling to keep the lights on
40/100 earnings predictability — expect surprises
-$0.25 fy2024 eps est
$115M fy2024 rev est
52.2% operating margin
xvary composite: 37/100 — weak
What they do
Gossamer Bio makes drugs for immune disease, inflammation, and cancer.
You are buying 144 employees and 3 drug programs, not a store with steady sales. Last quarter revenue was $35M, up 161% vs. prior year, while EPS (earnings per share, profit per share) was -$0.54. That gap is the whole story: the value sits in trial data, not in current sales.
How they make money
$115M
annual revenue
Collaboration revenue
$68M
License and milestone revenue
$25M
Grant revenue
$10M
Research service revenue
$8M
Other revenue
$4M
The products that matter
failed Phase 3 PAH asset
Seralutinib
>60% stock drop catalyst
The PROSERA Phase 3 trial in pulmonary arterial hypertension failed in February 2026. The stock lost more than 60% in a single day, which tells you how much of the old thesis sat in this one asset.
trial failed
earlier-stage PAH program
GB-0669
2025 pipeline pivot · $5B+ market
Management pivoted toward GB-0669 in 2025 after stepping back from the old respiratory strategy. The opportunity is a $5B+ PAH market, but there is no approved product here yet — only future data.
new focus
partner payments and milestones
Collaboration revenue
$44.1M · -58.2%
This is the current revenue stream, and it fell 58.2% to $44.1M over the trailing 12 months. That makes the funding picture look less like a business and more like a bridge.
shrinking cash source
Key numbers
$115M
annual revenue
This is real revenue, but it still sits next to a -52.2% operating margin, so the business is not close to self-funding.
52.2%
operating margin
For every $1 of sales, the company lost 52 cents at the operating line. That is the business model in one number.
$202M
long-term debt
Debt equals 67% of capital. That leaves less room for trial mistakes.
1.4
beta
A beta of 1.4 means the stock moves 40% more than the market. You get bigger swings than the index.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $202M (67% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for GOSS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Gossamer Bio posted $35M in quarterly revenue, and per-share loss was -$0.54.
Revenue was up 161% vs. prior year. The company is still a negative-earnings story, not a profits story.
$35M
revenue
$0.54
per-share loss
100.0%
gross margin
the number that mattered
Revenue was $35M because it shows the pipeline is producing cash before the company has a commercial drug.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the post-seralutinib reset failing to produce a credible replacement asset.
med
clinical hole in the pipeline
Seralutinib failed the PROSERA Phase 3 trial in February 2026, and the company has no other late-stage asset ready to take its place.
Impact: the old value driver is gone, so future upside now depends on earlier-stage programs with much lower visibility.
med
balance-sheet pressure
The company carries $202M in long-term debt, equal to 67% of capital, with a C+ balance sheet grade.
Impact: for a business with no approved products and a recent pipeline failure, financing risk moves closer to the center of the story.
med
shrinking collaboration revenue
Trailing 12-month revenue fell 58.2% to $44.1M. That revenue is partner-driven, not broad product demand.
Impact: non-dilutive cash is already falling while the company still lost $48.2M over the same period.
med
extreme stock volatility
Price stability is 5/100 and beta is 1.4. Those are warning labels, not decorations.
Impact: even if the business stabilizes, the stock can still move violently on thin coverage, financing headlines, or trial updates.
A company with $44.1M in trailing revenue, a $48.2M net loss, and no approved products does not have much room for another major setback.
source: institutional data · regulatory filings · risk analysis
Pay attention to
cash flow
Revenue versus burn
The company generated $44.1M in trailing revenue and still lost $48.2M. If collaboration revenue keeps falling, the financing question gets louder.
calendar
Q1 2026 earnings
Management commentary matters more than the quarter itself. You want to hear how they plan to fund the reset after seralutinib's failure.
pipeline
GB-0669 proof points
This is the new focal asset after the 2025 pivot. Any sign that GB-0669 can matter in PAH would change the conversation from liquidation math back to pipeline value.
street view
Target dispersion
The average analyst target is $5.43, but the median is $1.00. That spread tells you coverage is not a consensus. It is an argument.
Analyst rankings
earnings predictability
40 / 100
In human-speak, analysts do not trust the numbers to behave. Trial results matter more than spreadsheet precision.
beta
1.4
Beta measures market sensitivity. A 1.4 beta means the stock has tended to move about 14% when the market moves 10%.
price stability
5 / 100
That is extremely low. After a one-day drop of more than 60%, the rating is not being dramatic.
source: institutional data
Institutional activity
institutional ownership data for GOSS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive